Last reviewed · How we verify
methotrexate - etanercept - prednisolone arm
Methotrexate - etanercept - prednisolone is a marketed combination therapy developed by Seattle Children's Hospital, with a key composition patent expiring in 2028. The therapy leverages the well-established mechanisms of its components to address primary indications, though specific revenue figures are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | methotrexate - etanercept - prednisolone arm |
|---|---|
| Also known as | enbrel, prednisone |
| Sponsor | Seattle Children's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS (PHASE3)
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (PHASE4)
- Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis (PHASE2)
- Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis (PHASE4)
- Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: